Radiolabeling and biological evaluation of 125 I-Necitumumab for EGFR-targeted SPECT imaging
In this study, the SPECT probe125I-Necitumumab were synthesized and evaluated for SPECT imaging of non-small cell lung cancer (NSCLC). In vivo biodistribution study indicated that125I-Necitumumab was cleared rapidly in most organs and tissues. Though the tumor expressed a relatively high level of EGFR, however SPECT images showed no obvious uptake in the tumors. Therefore, we considered that125I-Necitumumab was not suitable for EGFR-targeted NSCLC SPECT imaging.
Source: Journal of Radioanalytical and Nuclear Chemistry - Category: Nuclear Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Chemistry | Lung Cancer | Non-Small Cell Lung Cancer | Nuclear Medicine | SPECT | Study